Between 10%-40% of newly diagnosed patents with acute myeloid leukemia (AML) do not achieve complete remission with intensive induction therapy and are therefore categorized as primary refractory or resistant. Few of these patients can be cured with conventional salvage therapy. They need to be evaluated regarding eligibility for allogeneic hematopoietic stem cell transplantation (HSCT) as this is currently the treatment with the highest probability of cure. To reduce the leukemia burden prior to transplantation, salvage chemotherapy regimens need to be employed. Whenever possible, refractory/relapsed patients should be enrolled in clinical trials as we do not have highly effective and standardized treatments for this situation. Novel therapies include tyrosine kinase inhibitors (TKIs), small molecule inhibitors (eg. for Polo-like kinase 1 (PLK-1), and aminopeptidase), inhibitors of mutated isocitrate dehydrogenase 1 (IDH1) and IDH2, antibody-based therapies and cell-based therapies. While the majority of these therapies are still under evaluation, they are likely to enter clinical practice rapidly as a bridge to transplant and/or in older, unfit patients who are not candidates for allogeneic HSCT. In this review we decribe our approach to refractory/ early relapsed AML and we discuss treatment options for patients with regard to different clinical conditions and molecular profiles.
Introduction
Primary refractory acute myeloid leukemia (AML) and early relapse remain among the most challenging scenarios in the management of AML. Primary refractory or resistant disease as defined by not achieving complete remission (CR), i.e. a remaining blast count of 5% or more after one to two cycles of intense induction therapy, 1 occurs in 10% -40% dependent of the patient population. Early relapse (mostly referred to by relapse within 6 months after CR1) 2 must be differentiated from late relapse (>6 months) as response to salvage therapy and overall survival is significantly different. 3, 4 Treatment decisions must be carefully taken and alternatives weighted against each other by looking at the complex picture of the patient and his age, performance status, comorbidities, cytogenetic findings, molecular profile and patient preference.
The first question that we need to ask is whether there are means of reducing the risk for refractory disease and early relapse by the selection of the initial therapy, i.e. is there a superior induction therapy compared to standard "7+3" (7 days of cytarabine and 3 days of anthracycline)? While daunorubicin at 90mg/m² certainly is superior to 45mg/m² both in younger and the fit older patients 5, 6 including patients with FLT3-ITD 7 , the direct comparison between daunorubicin 60mg/m 2 with 90mg/m 2 or 80mg/m 2 did not demonstrate any difference as to CR rate and overall survival 8, 9, 10 including patients with FLT3ITD 8 although higher dose daunorubicin might improve outcome in core-binding factor AML. 11 Thus, using 60-90mg/m² daunorubicin or 12mg/m² of idarubicin for three days is considered standard dosing. Whenever possible, we enroll newly diagnosed as well as relapsed patients into clinical trials. 12 In patients not fit for intensive chemotherapy, the induction therapy frequently has to be individualized taking patient and disease specific characteristics into account. 13 Outside trials, decitabine is our first choice for elderly patients unsuitable for intensive therapy. In countries where decitabine is not approved yet, low-dose cytarabine may be used instead. By introducing you to two patients from our practice we would like to illustrate how we make treatment decisions for this patient group.
Patient 1
A 37-year-old woman was diagnosed with AML with 95% bone marrow blasts and a white count of 110,000/µL. Genetic analyses revealed a normal karyotype, a fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) with a length of 78 nucleotides and an allelic ratio of 0.67, and wildtype NPM1 and CEBPA. Induction chemotherapy with ICE was started but the patient still showed 60% of blast in the bone marrow on day 15 indicating poor response. Therapy with FLA-IDA (fludarabine, cytarabine, idarubicine) 14 was immediately started as second induction cycle and in addition as a bridge to allogeneic HSCT. After this regimen the patient achieved a partial remission with 8% bone marrow blasts. After two weeks without further chemotherapy, conditioning with FLAMSA (fludarabine, amsacrine, cytarabine, 4 Gy total body irradiation (TBI)) 15 was initiated followed by allogeneic
HSCT from her HLA-identical sister. Unfortunately, she relapsed 132 days after
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After reduction of immunosuppressive therapy the patient was started on a regimen consisting of sorafenib and 5-azacytidine (AZA) based on phase-II data. 16 With this regimen and two additional donor lymphocyte infusions the patient's AML was moderately controlled for two months. The aim was a second allogeneic HSCT with an alternative donor, but unfortunately she died due to septicemia related to her underlying AML.
Discussion for Patient 1
Before diagnosing primary refractory disease, one has to define the time point when this has been determined. Primary refractory disease is usually diagnosed in patients who have not achieved CR after two cycles after induction chemotherapy 1 . Beyond this standard definition, it has consistently been shown that the prognosis is dismal in patients who are refractory to the first induction cycle as indicated by persistence of a substantial amount of bone marrow blasts at day 15 or who do not achieve at least a PR at day 21 to 35. [17] [18] [19] Taking this into account, response-adapted induction therapy with dose intensification during the second induction cycle is frequently 12, 19, 20 implemented in cases of insufficient response to first induction therapy as in our patient. In patient 1, the early assessment at day 15, which we rountinely do in our practice, opened the possibility to intensify treatment in a timely manner. Based on our recent analysis intensification using either high-dose cytarabine in combination with gemtuzumab ozogamicin and all-trans retinoic acid or a regimen based on highdose cytarabine plus fludarabine significantly improved the CR rate. 21 The latter is in might be in favor of a second cycle. After early relapse, our patient received sorafenib, a multi-tyrosin-kinase inhibitor in relapse after allogeneic HSCT. The use of a sorafenib in this situation holds some promise, as sorafenib may synergize with allogeneic immune effects to induce remissions. 26 Furthermore, there appears to be synergistic effects between sorafenib and azacitidine.
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Patient 2
A 58-year-old female who was treated with standard intense therapy (ICE) in our institution for core-binding factor AML with inversion 16 (inv16) (cKIT wildtype) in an If the patient is not a candidate for allogeneic HSCT (e.g. due to comorbidities or patient choice), we look at other treatment modalities including new drugs and/or palliative therapy with the aim to prolong patients` life with a meaningful quality of life ( Figure 1 ). Outside trials, we start with low-dose cytarabine mainly to control leukocyte counts combined with best supportive care (blood transfusions, antibiotic/antifungal treatment). In some of our frailest patients, hydroxurea or 6-mercaptopurine to control hyperleukocytosis is currently the only treatment option.
Palliative care services should be integrated in the patients' care. Calculations for the gain in quality-adjusted life-years (QALY) for different treatment options do not exist in Germany and are therefore not considered in our deliberations for treatment allocation.
Chemotherapy before allogeneic HSCT
If allogeneic HSCT is considered as best treatment option for the patient, we need to select the most promising salvage regimen to induce remission of the disease as a "bridge to transplantation". The aim of the salvage therapy is to reduce the leukemic burden, as one of the most significant factors for all survival endpoints after allogeneic HSCT is the disease status before allogeneic HSCT. The lower the leukemia burden prior to transplantation the better the outcome. we do not add G-CSF to this regimen as there is no data supporting its use.
However, idarubicin as an anthracycline appears to be an important drug in this combination as FLA alone (fludarabine, high-dose cytosine) was inferior to ADE (cytosine arabinoside, daunorubicin, and etoposide) as reinduction in a study for relapsed/refractory patients. 47 CR rates can be expected with this regimen in the range of 30% to 50%. 44 Other regimens are comparable in their effectiveness in this situation. For instance, daunorubicin has been replaced by mitoxantrone as an alternative anthracycline in combination with cytarabine and etoposide (MEC).
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High-dose cytarabine in combination with mitoxantrone (HAM) is also a common regimen in refractory/relapsed AML. 49 Adding other purine analogs to salvage chemotherapy is also practiced in this situation, but these drugs can increase toxicity.
The combination of clofarabine with high-dose cytarabine improved the response rate compared to high dose cytarabine alone but not overall survival. 50 Cladribine is also an important purine analog used in the treatment of relapsed childhood AML 51 while not fulfilling its promise in relapsed adult AML. 52 Sapacitabine is an oral purine analog that was investigated in elderly AML patients with newly diagnosed AML or relapsed AML showing some efficacy. 53 When elacytarabine was compared to 7
other commonly used AML salvage therapies according to investigator´s choice, outcome was not significantly different between patients receiving elacytarabine or treatment in the control arm. 54 Other modalidities of reducing treatment toxicity is Table 1 ) with regard to response rates (39.3% vs 27.6%), event-free survival (EFS) and overall survival (OS).
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Donor selection for allogeneic HSCT
Whenever possible, we aim for allogeneic transplantion for patients in second CR since there are essentially no cures with chemotherapy alone. However, if patients do not achieve a significant cytoreduction in the bone marrow or have more than 25%
blasts in bone marrow, we usually abstain from transplantation and recommend hypomethylating agents or trial participation (and reevaluation after these therapies). 
Novel targets
It is unlikely that patients with refractory AML will be cured solely by changing and 
Other targets
The quinolone derivative vosaroxin inhibits the topoisomerase II and acts independently of the p53 mutational staus. This drug was recently evaluated in combination with cytarabine (1g/m 2 on d1-5) in a phase 3 study in patients with refractory or relapsed AML. A benefit in overall survival of 1.4 months (7.5 months versus 6.1 months) was observed in the overall cohort that just missed significance.
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Inhibitors of cell division such as the polo-like kinase inhibitor (PLK-1) volasertib showed promise for AML patients. 82 The oral aminopeptidase inhibitor tosedostat was studied in a multicenter phase II trial (NCT00780598) in elderly patients with refractory/relapsed AML with an overall response rate of 22%.
Immunologic approaches
Immune based approaches including chimeric antigen receptor therapies (CAR) are still very immature and the immense operating expenses do not allow a general approach at this point. However, already well known immunomodulating agents such as lenalidomide might play a role in future AML therapy, especially in low proliferative disease. 83 Finally, epigenetic modifiers could help patients with relapsed/refractory patients.
Their role might be increased by combination therapy with novel agents (tosedostat, midostaurin) or as a bridge to allogeneic transplantation for less fit patients with the perspective of receiving RIC. This is based on the assumption that these drugs sensitize tumor cells to cytotoxic agents by re-expression of epigenetically silenced tumor suppressor genes.
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For personal use only. on August 31, 2017. by guest www.bloodjournal.org From In summary, the landscape of novel agents is very exciting and diverse. While some agents might only be applicable for molecularly defined subgroups of AML patients (eg. IDH1/2 mutations, FLT3-ITD, MLL-r), other agents hold promise for a broad unselected group of relapsed/refractory AML patients.
Perspective
The prognosis of refractory/early relapse AML patients remains poor even with allogeneic stem cell transplantation. Our insight into the molecular landscape of AML has dramatically increased with the introduction of next-generation sequencing as it has allowed us to identify novel genetic alterations including recurrent driver mutations. Functional analysis of these genetic aberrations has helped us to unravel the process of leukemogenesis further. For patients with refractory/early relapsed AML treatments arising out of these efforts present the most promising approaches. 
